CD19 CART cell therapies have shown remarkable efficacy in non-Hodgkin lymphoma. However, durable response has been observed in less than half of treated patients due to epitope loss and T cell exhaustion. To overcome this limitation, we developed a novel autologous BAFF-ligand based CART product (LMY-920) that targets BAFF receptors BAFFR/BR3, TACI and BCMA CAR-T capable of binding three different receptors, thereby minimizing the potential for antigen escape in the treatment of B cell cancers. Additionally, we improved manufacturing development time, cost, and efficiency using a novel TcBuster™ transposon system, which obviates the availability and cost hurdles associated with lentiviral vectors. GMP-grade transposon reagents can be generated in <4 months, the cost is lower than that of lentiviral vector and allows stable integration of >10K cargo.